Yüklüyor......
The R263K mutation in HIV integrase that is selected by dolutegravir may actually prevent clinically relevant resistance to this compound
INTRODUCTION: Drug resistance against dolutegravir (DTG) or the nucleosides with which it has been co-administered has never been observed in patients receiving this drug in first-line therapy. In contrast, a R263K mutation that confers low-level resistance (3–4 fold) to DTG has been selected by DTG...
Kaydedildi:
| Yayımlandı: | J Int AIDS Soc |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
International AIDS Society
2014
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4224880/ https://ncbi.nlm.nih.gov/pubmed/25394027 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.7448/IAS.17.4.19518 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|